A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis
Principal Investigator
Mitul Gandhi, MDLocations
Fairfax Office
Gainesville Office
Arlington Office
Alexandria Office
Loudoun Office
Learn More About This Trial
Other Relevant Trials
“An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101)”
Principal Investigator
Mitul Gandhi, MD“A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)”
